iTeos Therapeutics (ITOS) Competitors $10.15 +0.02 (+0.20%) Closing price 04:00 PM EasternExtended Trading$10.23 +0.08 (+0.83%) As of 06:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITOS vs. DYN, APGE, TWST, TVTX, BHVN, IMCR, CDTX, AUPH, WVE, and JANXShould you be buying iTeos Therapeutics stock or one of its competitors? The main competitors of iTeos Therapeutics include Dyne Therapeutics (DYN), Apogee Therapeutics (APGE), Twist Bioscience (TWST), Travere Therapeutics (TVTX), Biohaven (BHVN), Immunocore (IMCR), Cidara Therapeutics (CDTX), Aurinia Pharmaceuticals (AUPH), WAVE Life Sciences (WVE), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry. iTeos Therapeutics vs. Its Competitors Dyne Therapeutics Apogee Therapeutics Twist Bioscience Travere Therapeutics Biohaven Immunocore Cidara Therapeutics Aurinia Pharmaceuticals WAVE Life Sciences Janux Therapeutics Dyne Therapeutics (NASDAQ:DYN) and iTeos Therapeutics (NASDAQ:ITOS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, valuation, earnings, profitability and media sentiment. Do institutionals and insiders hold more shares of DYN or ITOS? 96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 97.2% of iTeos Therapeutics shares are owned by institutional investors. 14.1% of Dyne Therapeutics shares are owned by insiders. Comparatively, 14.2% of iTeos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, DYN or ITOS? Dyne Therapeutics has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. Comparatively, iTeos Therapeutics has a beta of 1.49, meaning that its stock price is 49% more volatile than the S&P 500. Does the media refer more to DYN or ITOS? In the previous week, Dyne Therapeutics had 15 more articles in the media than iTeos Therapeutics. MarketBeat recorded 17 mentions for Dyne Therapeutics and 2 mentions for iTeos Therapeutics. iTeos Therapeutics' average media sentiment score of 1.44 beat Dyne Therapeutics' score of 1.17 indicating that iTeos Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 10 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive iTeos Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer DYN or ITOS? Dyne Therapeutics currently has a consensus target price of $34.07, suggesting a potential upside of 147.76%. iTeos Therapeutics has a consensus target price of $15.50, suggesting a potential upside of 52.71%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Dyne Therapeutics is more favorable than iTeos Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Dyne Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 3 Strong Buy rating(s) 3.06iTeos Therapeutics 0 Sell rating(s) 6 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.14 Which has better earnings and valuation, DYN or ITOS? Dyne Therapeutics is trading at a lower price-to-earnings ratio than iTeos Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioDyne TherapeuticsN/AN/A-$317.42M-$3.86-3.56iTeos TherapeuticsN/AN/A-$134.41M-$4.67-2.17 Is DYN or ITOS more profitable? iTeos Therapeutics' return on equity of -33.26% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Dyne TherapeuticsN/A -64.12% -56.75% iTeos Therapeutics N/A -33.26%-28.16% SummaryiTeos Therapeutics beats Dyne Therapeutics on 8 of the 14 factors compared between the two stocks. Get iTeos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ITOS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ITOS vs. The Competition Export to ExcelMetriciTeos TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$447.80M$3.10B$5.78B$9.80BDividend YieldN/A2.26%3.95%4.02%P/E Ratio-2.1721.0831.2626.59Price / SalesN/A364.13454.13168.41Price / CashN/A44.6737.7359.36Price / Book0.918.0910.046.68Net Income-$134.41M-$54.08M$3.27B$265.59M7 Day Performance-0.49%2.25%3.17%3.42%1 Month Performance0.40%3.41%4.34%1.09%1 Year Performance-40.82%18.61%44.12%23.84% iTeos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ITOSiTeos Therapeutics2.7607 of 5 stars$10.15+0.2%$15.50+52.7%-41.6%$447.80MN/A-2.1790Positive NewsHigh Trading VolumeDYNDyne Therapeutics3.5786 of 5 stars$12.33-0.4%$33.80+174.1%-69.0%$1.76BN/A-3.19100Positive NewsAnalyst UpgradeAPGEApogee Therapeutics3.7515 of 5 stars$36.90-1.0%$99.00+168.3%-20.5%$1.72BN/A-8.9391Positive NewsAnalyst ForecastTWSTTwist Bioscience4.0393 of 5 stars$28.02-0.4%$49.40+76.3%-39.7%$1.70B$312.97M-19.32990Positive NewsTVTXTravere Therapeutics2.3282 of 5 stars$18.77-0.3%$32.21+71.6%+92.5%$1.68B$233.18M-9.20460Analyst ForecastGap UpBHVNBiohaven3.8099 of 5 stars$16.02+2.0%$53.75+235.5%-62.3%$1.66BN/A-2.09239IMCRImmunocore1.591 of 5 stars$32.31-1.7%$58.00+79.5%-9.7%$1.66B$310.20M-80.78320Positive NewsAnalyst ForecastCDTXCidara Therapeutics3.6259 of 5 stars$63.24-3.0%$64.14+1.4%+404.2%$1.65B$1.27M-5.6890Positive NewsAUPHAurinia Pharmaceuticals2.2545 of 5 stars$12.22-0.4%$12.00-1.8%+79.9%$1.62B$260.11M28.42300Positive NewsWVEWAVE Life Sciences4.7744 of 5 stars$9.74-0.2%$20.27+108.1%+78.4%$1.55B$93.95M-10.82240Insider TradeJANXJanux Therapeutics2.5501 of 5 stars$25.53+1.7%$91.89+259.9%-48.3%$1.51B$10.59M-14.1830News CoveragePositive News Related Companies and Tools Related Companies DYN Competitors APGE Competitors TWST Competitors TVTX Competitors BHVN Competitors IMCR Competitors CDTX Competitors AUPH Competitors WVE Competitors JANX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ITOS) was last updated on 8/28/2025 by MarketBeat.com Staff From Our PartnersBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredSmall Washington, DC Group Could Crash US StocksNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredThis strange black card is showing up across America"THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access